Functional assessment of p53 in chronic lymphocytic leukemia

Blood Cancer Journal

Volumn 1, Issue 2, 2011, Pages

  Le Garff Tavernier, M ^a,b,c   Blons, H ^d   Nguyen Khac, F ^a,b,e   Pannetier, M ^a   Brissard, M ^a   Gueguen, S ^a   Jacob, F ^b,e   Ysebaert, L ^f   Susin, S A ^b,e   Merle Beral H ^a,b,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; CD38 ANTIGEN; PROTEIN KINASE ZAP 70; PROTEIN P53;

ALLELE; ANTIGEN EXPRESSION; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME 11; CHROMOSOME 11Q23; CHROMOSOME 17; CHROMOSOME 17P13; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; EPIGENETICS; GENE MUTATION; GENE SILENCING; HUMAN; INTRON; LETTER; PROTEIN EXPRESSION;

EID: 84864054048     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.3     Document Type: Letter

References (8)

1. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1926.
2. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184. (Pubitemid 34864269)
3. Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322-3329.
4. Best OG, Gardiner AC, Majid A, Walewska R, Austen B, Skowronska A et al. A novel functional assay using etoposide plus nutlin- 3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008; 22: 1456-1459. (Pubitemid 352006096)
5. Bode Ann M, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4: 793-805. (Pubitemid 39331151)
6. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993-1000. (Pubitemid 44154636)
7. Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 2252-2257.
8. Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009; 113: 3801-3808.